Authors
Latest:
Findings of the IMMUTACE Trial in Hepatocellular CarcinomaArndt Vogel, MD, discusses the study results of the IMMUTACE study in hepatocellular carcinoma.
Latest:
Analysis Explores Impact of Increased Point Mutations With High-Dose Melphalan in MyelomaMehmet K. Samur, PhD, discusses findings from an analysis evaluating high-dose melphalan followed by autologous stem cell transplant as treatment of patients with multiple myeloma compared with the standard of care treatment regimen lenalidomide, bortezomib, and dexamethasone alone.
Latest:
PFS Data Support Approval of Fam-Trastuzumab Deruxtecan-nxki for HER2+ Breast CancerYeon Hee Park, MD, discusses the data supporting the FDA’s accelerated approval of fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ≥2 prior anti–HER2-based regimens in the metastatic setting.
Latest:
About the Continued Evaluation of MK-1084 for NSCLC and MoreCarlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.
Latest:
Azacitadine Plus Pevonedistat Shows Efficacy in MDS/CMML or LB AMLMikkael Sekeres, MD, discusses a phase 2 study of pevonedistat plus azacitidine versus azacitadine monotherapy in patients with higher-risk myelodysplastic syndromes /chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia.
Latest:
Evaluating Ways of Measuring MRD in Hematologic MalignanciesJerald P. Radich, MD, discusses how minimal residual disease is measured in hematologic malignancies.
Latest:
Racial Disparity Seen in Use of Germline Testing in TNBCNicholas J. Robert, MD, discusses a study of the social determinants of a patient’s health related to the use of genomic testing in women with breast cancer.
Latest:
The Gut Microbiome and Immunotherapy: New Research Explores CBM588's Mechanism in mRCCHedyeh Ebrahimi, MD, MPH, discusses a study that found adding the live bacterial product CBM588 to standard immunotherapy potentially impacted patients' responses in renal cell carcinoma.
Latest:
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOCIn heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Latest:
Futibatinib Shows Promise in Breast Cancer With FGFR1 Gene AmplificationsSenthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.
Latest:
Can Just-in-Time Clinical Trials Reduce Disparities in Participation?Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.
Latest:
Survival Advantage Observed in HER2+Breast Cancer With Brain MetastasisNancy U. Lin, MD, discusses the results from a substudy of HER2CLIMB looking at tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer and brain metastases.
Latest:
Biomarker Analysis Predicts Post-Osimertinib Response in EGFR+ NSCLCBenjamin Besse, MD, PhD, discusses the biomarker analysis of the phase 1/1b CHRYSALIS-2 study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Latest:
In mCRPC, Prior Abiraterone Treatment Plus Lutetium Lu 177 Vipivotide Tetraxetan Improves OutcomesImproved outcomes with lutetium Lu 177 vipivotide tetraxetan vs ARPI change supported prior treatment with abiraterone vs enzalutamide in mCRPC.
Latest:
Increased Rates of Viral Infections in Multiple MyelomaHeinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.
Latest:
Outcomes Underscore Need for New Agents to Treat Anaplastic Thyroid CarcinomaChristine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.
Latest:
Comparing Tandem Stem Cell Transplant Approaches in Multiple MyelomaNicolaus Kröger, MD, discusses the advantages of autologous stem cell transplant and allogeneic stem cell transplant compared with autologous tandem transplant in patients with multiple myeloma.
Latest:
JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCCThe potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.
Latest:
Improving Upon Immunotherapy Advances in HCCBruno Sangro, MD, PhD, discusses the key takeaways from recent data in the treatment landscape of patients with hepatocellular carcinoma.
Latest:
Unmet Needs Remain Unfilled in the Diffuse Large B-Cell Lymphoma SpaceThomas Habermann, MD, discusses the unmet clinical needs which still exist for patients with diffuse large B-cell lymphoma.
Latest:
Colorectal Cancer Awareness Month: Overcoming Barriers to Early DetectionCharles Meakin, MD, MHA, chief medical officer of Care Oncology, discusses the current colorectal cancer landscape, innovations in detection, and improving patient screening and follow-up care for Colorectal Cancer Awareness Month.
Latest:
Overview of HER2-Targeting Agents in Breast Cancer and Treatment Selection ApproachesA medical oncologist provides a comprehensive overview of HER2-targeting agents in breast cancer and considerations to factor into treatment decisions.
Latest:
Artificial Intelligence and Machine Learning in Cancer DetectionArtificial intelligence and machine learning dramatically alter how medicine is practiced, and cancer detection is no exception, according to Toufic Kachaamy, MD of City of Hope Phoenix.
Latest:
Daratumumab Regimen May Be the More Active Therapy Needed for AmyloidosisEfstathios Kastritis, MD, discusses the amyloidosis setting, current standards of care, and the phase 3 ANDROMEDA trial.
Latest:
Confronting Challenges and Embracing Progress in HER2+ Breast CancerYara Abdou, MD, looks back on what have been the biggest challenges in treating HER2-positive breast cancer over the past 5-10 years.
Latest:
Precise Management of EGFR exon 20-Positive Non–Small Cell Lung CancerResearch shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.
Latest:
Company-wide Initiative Will Provide Standards for Collection and StorageThe Florida Cancer Specialists & Research Institute's Data Governance Committee was established to oversee the program’s implementation and monitor its progress.
Latest:
The Promise of ALLO-501A in Relapsed/Refractory LBCLMichael T. Tees, MD, discusses the data behind ALLO-501A, an allogeneic chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma.
